AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29301463 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling catheter duration
Number of subjects: 80
Study 29301486 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA) using multidimensional prognostic index (MPI)
Number of subjects: 71
Study 29301486 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA) using short physical performance battery (SPPB)
Number of subjects: 71
Study 29301486 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver Code (based on administrative data)
Number of subjects: 71
Study 29301519 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-driven knowledge translation program for improved hand hygiene and aseptic techniques
Number of subjects: 0
Study 29301519 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated interprofessional dialogue and learning
Number of subjects: 0
Study 29301519 — intervention group
Group type: EXPERIMENTAL
Intervention: Shift from one-way directed compliance to participatory and meaning-making process
Number of subjects: 0
Study 29301522 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus e-mail alerts to family physicians and nurses regarding low metabolic indexes.
Number of subjects: 0
Study 29301522 — intervention group
Group type: COMPARATOR
Intervention: Usual care without e-mail alerts.
Number of subjects: 0
Study 29301545 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized training with a-tDCS (group 1)
Number of subjects: 0
Study 29301545 — intervention group
Group type: COMPARATOR
Intervention: Personalized training with sham-tDCS (group 2)
Number of subjects: 0
Study 29301545 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-personalized training with a-tDCS (group 3)
Number of subjects: 0
Study 29301580 — intervention group
Group type: EXPERIMENTAL
Intervention: BIP48 (pegylated interferon alfa-2b from Bio-Manguinhos/Fiocruz, Brazil)
Number of subjects: 31
Study 29301580 — intervention group
Group type: COMPARATOR
Intervention: PEGASYS® (pegylated interferon alfa-2a from Roche Pharmaceutical)
Number of subjects: 31
Study 29301628 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-derived MRP-14
Number of subjects: 0
Study 29301628 — intervention group
Group type: COMPARATOR
Intervention: Antibody-mediated blockade
Number of subjects: 0
Study 29301628 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating MRP-14
Number of subjects: 0
Study 29301865 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-HPLC-electron capture atmospheric pressure chemical ionization/high-resolution MS
Number of subjects: 0
Study 29301921 — intervention group
Group type: EXPERIMENTAL
Intervention: Living well with COPD (LWWCOPD) self-management intervention
Number of subjects: 467
Study 29301924 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29301973 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Pressure Variability (BPV) in the hyperacute phase (0 to 4-6 hours after onset)
Number of subjects: 386
Study 29301973 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Pressure Variability (BPV) in the acute phase (0 to 24-26 hours after onset)
Number of subjects: 386
Study 29301973 — intervention group
Group type: EXPERIMENTAL
Intervention: First systolic BP recorded at median 23 minutes after onset
Number of subjects: 386
Study 29301973 — intervention group
Group type: EXPERIMENTAL
Intervention: Second systolic BP recorded at emergency department arrival at 57 minutes after onset
Number of subjects: 386
Study 29301973 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic BP 24 hours after arrival
Number of subjects: 386
Study 29301973 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfavorable outcome at 3 months (modified Rankin Scale, 3-6)
Number of subjects: 386
Study 29302336 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular bioscaffolds composed of mammalian extracellular matrix (ECM) implanted with aggressive and early physical therapy
Number of subjects: 13
Study 29302336 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular bioscaffolds with physical therapy
Number of subjects: 13
Study 29303843 — intervention group
Group type: EXPERIMENTAL
Intervention: LTNPs
Number of subjects: 88
Study 29303843 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressors
Number of subjects: 88
Study 29303843 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 88
Study 29304371 — intervention group
Group type: EXPERIMENTAL
Intervention: Rare coding variants in ANGPTL6 (specifically the c.1378A>T allele)
Number of subjects: 95
Study 29304371 — intervention group
Group type: EXPERIMENTAL
Intervention: Rare coding variants in ANGPTL6
Number of subjects: 95
Study 29304371 — intervention group
Group type: EXPERIMENTAL
Intervention: ANGPTL6 variants
Number of subjects: 95
Study 29304371 — intervention group
Group type: EXPERIMENTAL
Intervention: History of high blood pressure
Number of subjects: 95
Study 29304421 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40IU)
Number of subjects: 86
Study 29304421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 29304833 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor (80 mg/day) in combination with high-dose cytarabine and mitoxantrone (HiDAC/Mito)
Number of subjects: 20
Study 29304833 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor (60 mg)
Number of subjects: 20
Study 29305069 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time feedback in the home plus brief coaching of parents or guardians.
Number of subjects: 298
Study 29305069 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 298
Study 29305093 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative fluorescence angiography after tibial bypass surgery
Number of subjects: 40
Study 29305093 — intervention group
Group type: COMPARATOR
Intervention: Direct revascularised angiosomes (DR)
Number of subjects: 40
Study 29305116 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary total plasmin(ogen)/creatinine ratio and plasma concentration of aldosterone
Number of subjects: 0
Study 29305116 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine albumin
Number of subjects: 0
Study 29305116 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoglobin A
Number of subjects: 0
Study 29305315 — intervention group
Group type: EXPERIMENTAL
Intervention: RELA haploinsufficiency
Number of subjects: 0
Study 29305501 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus supplementation or intervention, specific dosage and duration not mentioned
Number of subjects: 0
Study 29305501 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Lactobacillus intervention), details not specified
Number of subjects: 0
Study 29305552 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (initiated at 20 mg daily, ramped up to 400 mg daily)
Number of subjects: 36
Study 29305552 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax
Number of subjects: 36
Study 29305734 — intervention group
Group type: EXPERIMENTAL
Intervention: Olipudase alfa
Number of subjects: 5
Study 29305847 — intervention group
Group type: COMPARATOR
Intervention: Wheelchair users alone
Number of subjects: 152
Study 29305847 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair users blended with caregivers
Number of subjects: 152
Study 29305947 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum food intake (3-day average)
Number of subjects: 61
Study 29305947 — intervention group
Group type: EXPERIMENTAL
Intervention: Overeating 100 Kcal/d above the food intake predicted by 24-h EE at baseline
Number of subjects: 61
Study 29305947 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fat intake
Number of subjects: 61
Study 29305947 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate intake
Number of subjects: 61
Study 29305947 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake
Number of subjects: 61
Study 29306043 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir and Sofosbuvir for 12 weeks
Number of subjects: 667
Study 29306043 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir and Sofosbuvir for 24 weeks
Number of subjects: 667
Study 29306043 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir and Sofosbuvir with Ribavirin for 12 weeks
Number of subjects: 667
Study 29306043 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir and Sofosbuvir with Ribavirin for 24 weeks
Number of subjects: 667
Study 29306203 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed low-dose rate radiotherapy (PLDR) - 10 fractions of 2 Gy/day, with an interval of 3 minutes, for 5 days per week; dose rate 6.67 cGy/min
Number of subjects: 22
Study 29306203 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed low-dose rate radiotherapy (PLDR)
Number of subjects: 22
Study 29306459 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum uric acid (sUA) levels
Number of subjects: 7531
Study 29306459 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum uric acid (sUA) levels (using diuretics)
Number of subjects: 7531
Study 29306459 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum uric acid (sUA) levels (not using diuretics)
Number of subjects: 7531
Study 29306506 — intervention group
Group type: COMPARATOR
Intervention: On-time dosing (control group)
Number of subjects: 1321
Study 29306506 — intervention group
Group type: EXPERIMENTAL
Intervention: Substantially late dose 3 (group 2)
Number of subjects: 1321
Study 29306506 — intervention group
Group type: EXPERIMENTAL
Intervention: Substantially late dose 2, on-time dose 3 (group 3)
Number of subjects: 1321
Study 29306506 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses substantially late (group 4)
Number of subjects: 1321
Study 29306506 — intervention group
Group type: EXPERIMENTAL
Intervention: On-time dose 2
Number of subjects: 1321
Study 29306506 — intervention group
Group type: EXPERIMENTAL
Intervention: Substantially late dose 2
Number of subjects: 1321
Study 29306506 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants ≥15 years old
Number of subjects: 1321
Study 29306587 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 11422
Study 29306587 — intervention group
Group type: EXPERIMENTAL
Intervention: Death after surgery
Number of subjects: 11422
Study 29306587 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection as a complication
Number of subjects: 11422
Study 29306769 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab at a dose of 10 mg/kg in week 1, 4, 7, 10 followed by 3-month maintenance treatment for a maximum of 48 weeks
Number of subjects: 25
Study 29306769 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 25
Study 29306872 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressors (66 patients, 22.5%)
Number of subjects: 326
Study 29306872 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model including mRSS and duration of skin thickening
Number of subjects: 326
Study 29306872 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model including mRSS, duration of skin thickening, and Pol3 positivity
Number of subjects: 326
Study 29306876 — intervention group
Group type: EXPERIMENTAL
Intervention: Perinatal depression diagnosed in the first trimester of pregnancy
Number of subjects: 568
Study 29307383 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive women who acquired HIV after migration
Number of subjects: 980
Study 29307383 — intervention group
Group type: COMPARATOR
Intervention: Women without HIV
Number of subjects: 980
Study 29307383 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive women who acquired HIV before migration
Number of subjects: 980
Study 29307520 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal muscle ceramides in T2DM
Number of subjects: 0
Study 29307520 — intervention group
Group type: COMPARATOR
Intervention: Fat oxidation rates in ND
Number of subjects: 0
Study 29307520 — intervention group
Group type: COMPARATOR
Intervention: Fat oxidation and 24-h RQ
Number of subjects: 0
Study 29307520 — intervention group
Group type: COMPARATOR
Intervention: Muscle ceramides in ND
Number of subjects: 0
Study 29307536 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprovoked venous thromboembolism
Number of subjects: 991
Study 29307536 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal deep vein thrombosis
Number of subjects: 991
Study 29307536 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent venous thromboembolism
Number of subjects: 991
Study 29307536 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-fatality of recurrence
Number of subjects: 991
Study 29307722 — intervention group
Group type: COMPARATOR
Intervention: Internet-based exercise training (IBET)
Number of subjects: 350
Study 29307722 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (PT)
Number of subjects: 350
Study 29308669 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppression regimen (basiliximab, tacrolimus, mycophenolate, and prednisone)
Number of subjects: 31
Study 29309249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 658
Study 29309249 — intervention group
Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 658
Study 29309319 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk group (50 mg/kg TXA bolus)
Number of subjects: 48
Study 29309319 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group (loading dose 30 mg/kg, infusion 16 mg/kg/h with 2 mg/kg in pump prime)
Number of subjects: 48
Study 29309319 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 29309521 — intervention group
Group type: EXPERIMENTAL
Intervention: Live zoster vaccine
Number of subjects: 1400000
Study 29309629 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 143
Study 29310641 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment (specifics not provided)
Number of subjects: 13
Study 29310641 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaires (EuroQoL EQ-5D-5 L, EORTC QLQ-C30, QLQ-BR23, Hospital Anxiety and Depression Scale)
Number of subjects: 13
Study 29310710 — intervention group
Group type: EXPERIMENTAL
Intervention: Active LLLT (low-level laser therapy)
Number of subjects: 36
Study 29310710 — intervention group
Group type: COMPARATOR
Intervention: Sham LLLT (placebo group)
Number of subjects: 36
Study 29310869 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous vascular access
Number of subjects: 13155
Study 29310869 — intervention group
Group type: COMPARATOR
Intervention: Intravenous vascular access
Number of subjects: 13155
Study 29310928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg) and velpatasvir (100 mg) once daily for 12 weeks
Number of subjects: 103
Study 29310998 — intervention group
Group type: EXPERIMENTAL
Intervention: Excess visceral adipose tissue (VAT) ≥100 cm²
Number of subjects: 118
Study 29310998 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic dysfunction
Number of subjects: 118
Study 29310998 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcifications (CAC)
Number of subjects: 118
Study 29310998 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT)
Number of subjects: 118
Study 29311069 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem-Vaborbactam, single-dose administration, specific dosage not mentioned.
Number of subjects: 0
Study 29311086 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine; specific dosage and duration not provided
Number of subjects: 0
Study 29311094 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin at fixed doses
Number of subjects: 0
Study 29311357 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 242
Study 29311357 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical sleeve gastrectomy
Number of subjects: 242
Study 29312109 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy after alteplase
Number of subjects: 70
Study 29312109 — intervention group
Group type: COMPARATOR
Intervention: Alteplase-only
Number of subjects: 70
Study 29312109 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Number of subjects: 70
Study 29312116 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG-driven NMES-robotic hand-assisted upper-limb training
Number of subjects: 0
Study 29312123 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-months supervised endurance/strength training
Number of subjects: 0
Study 29312123 — intervention group
Group type: COMPARATOR
Intervention: Control group (age/gender-matched individuals)
Number of subjects: 0
Study 29312761 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty (BT)
Number of subjects: 0
Study 29312761 — intervention group
Group type: EXPERIMENTAL
Intervention: China Alair System Registry Study (NCT02206269)
Number of subjects: 0
Study 29312786 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol plus Fentanyl
Number of subjects: 100
Study 29312786 — intervention group
Group type: COMPARATOR
Intervention: Midazolam plus Fentanyl
Number of subjects: 100
Study 29312948 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled diet of 1.2 g/kg protein for 2 days
Number of subjects: 0
Study 29313106 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-related cues
Number of subjects: 31
Study 29313106 — intervention group
Group type: COMPARATOR
Intervention: Neutral stimuli
Number of subjects: 31
Study 29313223 — intervention group
Group type: EXPERIMENTAL
Intervention: Population Health Coordinator (PHC) plus Information Technology (IT) system
Number of subjects: 41555
Study 29313223 — intervention group
Group type: COMPARATOR
Intervention: Information Technology (IT) system alone
Number of subjects: 41555
Study 29313267 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 2536
Study 29313267 — intervention group
Group type: COMPARATOR
Intervention: Placebo or Sitagliptin
Number of subjects: 2536
Study 29313282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg once daily and Sitagliptin 100 mg once daily (E5/S100)
Number of subjects: 291
Study 29313282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg once daily and Sitagliptin 100 mg once daily (E15/S100)
Number of subjects: 291
Study 29313282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study 29313282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin/Sitagliptin groups
Number of subjects: 291
Study 29313282 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 291
Study 29313714 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-bronchodilator FEV1
Number of subjects: 396
Study 29313714 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary function testing
Number of subjects: 396
Study 29314424 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 3496
Study 29314424 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 3496
Study 29314487 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessment of neck veins
Number of subjects: 0
Study 29315015 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced expression of a dominant-negative TGF-β receptor type 2 (DNRII)
Number of subjects: 8
Study 29315307 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir exposure
Number of subjects: 0
Study 29315307 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29315327 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher quality of care
Number of subjects: 1053
Study 29315327 — intervention group
Group type: COMPARATOR
Intervention: Quality of care
Number of subjects: 1053
Study 29315327 — intervention group
Group type: EXPERIMENTAL
Intervention: Family planning programs with higher quality of care
Number of subjects: 1053
Study 29315382 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact force-sensing catheter ablation
Number of subjects: 261
Study 29315999 — intervention group
Group type: EXPERIMENTAL
Intervention: Acotiamide 100 mg three times daily for 1 year
Number of subjects: 0
Study 29316001 — intervention group
Group type: EXPERIMENTAL
Intervention: ledipasvir/sofosbuvir for 8 weeks
Number of subjects: 40
Study 29316837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (JAK1/JAK2 inhibitor)
Number of subjects: 0
Study 29316837 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids (standard first-line treatment)
Number of subjects: 0
Study 29316897 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents with higher AOD risk and lower mental health scores
Number of subjects: 1279
Study 29316897 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents asked by a medical provider about AOD use
Number of subjects: 1279
Study 29316897 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents at risk for AOD use and poor mental health
Number of subjects: 1279
Study 29317222 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical performance measures including muscle strength and mobility at discharge
Number of subjects: 75
Study 29317222 — intervention group
Group type: EXPERIMENTAL
Intervention: Total paretic lower limb torque and 6-minute walk test
Number of subjects: 75
Study 29317222 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical performance measures
Number of subjects: 75
Study 29317381 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus full-time use of social networks (Facebook) for education and consultation.
Number of subjects: 128
Study 29317381 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment.
Number of subjects: 128
Study 29317417 — intervention group
Group type: EXPERIMENTAL
Intervention: New group-based treatment programme combining physical exercise and dietary therapy
Number of subjects: 15
Study 29317417 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 15
Study 29317604 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma kynurenine (KYN) concentrations
Number of subjects: 290
Study 29317604 — intervention group
Group type: EXPERIMENTAL
Intervention: DEFB1 locus
Number of subjects: 290
Study 29317604 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional studies of DEFB1
Number of subjects: 290